scholarly journals Preliminary results of dulaglutide treatment in patients with non-alcoholic fatty liver disease (DEMOS study)

2020 ◽  
pp. 4-10
Author(s):  
P. O. Bogomolov ◽  
A. O. Bueverov ◽  
A. V. Dreval ◽  
O. A. Nechaeva ◽  
A. Yu. Mayorov ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Open Label ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Fatty Liver Index ◽  
Glucose And Lipid Metabolism ◽  
Alcoholic Fatty Liver Disease

65 patients with nonalcoholic fatty liver disease (NAFLD) were included in open-label observative prospective cohort study. Mean age was 54.8 ± 10.5 y. o. All patients were treated with metformin before and during the study. All patients were treated by GLP-1 receptor agonist dulaglutide subcutaneously weekly 26 weeks. Patients of group with type 2 diabetes were treated with dulaglutide 0.75 mg weekly 2 weeks, than 1.5 weekly 24 weeks. Patients of group without diabetes were treated by dulaglutide 0.75 mg weekly 4 weeks, than 1.5 weekly 22 weeks. Both groups of patients were demonstrated significant reduce of body weight, BMI, waist circumference, glucose, HbA1c, insulin resistance indexes, transaminases and gamma-glutamyltranspeptidase activity. Fatty liver index and liver stiff ness also decreased after treatment. We can conclude that dulaglutide treatment in NAFLD patients decreases body wieight, improves glucose and lipid metabolism and decreases inflammatory activity of steatohepatitis.

scholarly journals Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population

2016 ◽  
Vol 89 (1) ◽  
pp. 82-88 ◽  
Author(s):  
Cristina Alina Silaghi ◽  
Horatiu Silaghi ◽  
Horatiu Alexandru Colosi ◽  
Anca Elena Craciun ◽  
Anca Farcas ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Ldl Cholesterol ◽  
Diabetic Patients ◽  
Alcoholic Fatty Liver ◽  
Liver Index ◽  
Fatty Liver Index ◽  
Alcoholic Fatty Liver Disease

Background and aims. We aimed to study prevalence  and the predictive factors of non-alcoholic fatty liver disease (NAFLD) defined by the fatty liver index (FLI) in type 2 diabetic patients (T2DM).Methods. Three hundred and eighty-one T2DM outpatients who regularly attended a Consulting Clinic in Cluj were retrospectivelly included. FLI, a surrogate steatosis biomarker based on body mass index (BMI), waist circumference (WC), triglycerides (TGL) and gammaglutamyl-transferase (GGT) was used to assess NAFLD in all patients. Anthropometric and biochemical parameters were measured. Hepatic steatosis (HS) was evaluated by ultrasonography.Results. NAFLD-FLI (defined as FLI >60) was correlated with HS evaluated by ultrasound (r=0.28; p<0.001). NAFLD-FLI was detected in 79% of T2DM. The prevalence of obesity in NAFLD-FLI patients was 80%. Of the patients with normal alanine aminotransferase (ALAT), 73.8 % had NAFLD. At univariate analysis, NAFLD-FLI was correlated with age (r= -0.14; p=0.007), sex (r=0.20; p<0.001), LDL cholesterol (r=0.12; p=0.032), HDL cholesterol (r = -0.13; p=0.015), ALAT (r=0.20; p<0.001) and ASAT (r=0.19; p<0.001). At multiple regression analysis, sex, ALAT and LDL-cholesterol were independent predictors of NAFLD-FLI. After logistic regression model, ALAT, LDL-cholesterol, HOMA-IR were good independent predictors of NAFLD-FLI.Conclusions. NAFLD-FLI could be useful to identify NAFLD in T2DM patients. Subjects with T2DM had a high prevalence of NADLD-FLI even with normal ALAT levels . Our findings showed that sex, ALAT, LDL cholesterol and IR were significant and independent factors associated with the presence of NAFLD in T2DM subjects.

scholarly journals Validation of Fatty Liver Index as a Marker for Non-Alcoholic Fatty Liver Disease

2021 ◽  
Vol 21 (2) ◽  
pp. 56-62
Author(s):  
Seong-Won Park ◽  
A-Lum Han
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Health Examination ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Liver Index ◽  
Fatty Liver Index ◽  
Alcoholic Fatty Liver Disease

Background: Many studies have been conducted to validate fatty liver index (FLI) as a marker for non-alcoholic fatty liver disease (NAFLD). However, there are insufficient data in Korea to verify the usefulness of FLI, and the results of these studies are contradictory. This study aimed to validate FLI as a marker for NAFLD in Korea. For better accuracy, computed tomography (CT) scan was used instead of ultrasound scan.Methods: A cross-sectional analysis was performed in 785 subjects who participated in a health examination. The participants were divided according to presence of NAFLD, which was determined by abdominal CT. Frequency analysis was performed on all results. The chi-square test and independent t-test were used to compare the differences between the non-NAFLD group and the NAFLD group in terms of general characteristics and blood tests. The ability of the FLI to detect (nonalcoholic) fatty liver was assessed using area under the receiver operator characteristic (AUROC) curve analysis.Results: FLI was significantly higher in the NAFLD group (42.48±27.63) than in the non-NAFLD group (22.59±20.05) (P<0.0001). The algorithm for FLI had a better AUROC of 0.696 (95% confidence interval, 0.649-0.742) than any other variable in the prediction of NAFLD.Conclusions: FLI is a marker that can be used as a simple and cost-effective tool to screen for NAFLD.

scholarly journals Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)

2021 ◽  
Vol 53 (1) ◽  
pp. 1256-1264
Author(s):  
Daniel J. Cuthbertson ◽  
Juha Koskinen ◽  
Emily Brown ◽  
Costan G. Magnussen ◽  
Nina Hutri-Kähönen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Liver Index ◽  
Fatty Liver Index ◽  
Alcoholic Fatty Liver Disease

scholarly journals RISK FACTORS ASSOCIATED WITH TYPE 2 DIABETES MELLITUS AND THE FREQUENCY OF NAFLD AFFECTED PATIENTS

2021 ◽  
Vol 9 (07) ◽  
pp. 11-15
Author(s):  
Rehana Ahmed ◽  
◽  
Mahrukh Hamed ◽  
Nebela Khan ◽  
Saurabh Singh ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Diabetics have a higher risk of developing nonalcoholic fatty liver disease (NAFLD) and associated complications than the general population. The purpose of this study was to determine the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with type 2 diabetes, as well as the demographic, metabolic, and biochemical features associated with it. Material and methods: This was a prospective, observational, descriptive (cross-sectional), and non-interventional research on a cohort of type 2 diabetes mellitus patients conducted in a hospital setting. Over the course of 18 months, this study was done (August 2019 to March 2021). Results: A total of 100 patients were enrolled, with 63 (63%) being Females and 64 (37%) being men. Age, BMI, and diabetes duration all had statistically significant positive correlations with the prevalence of nonalcoholic fatty liver disease. Overall prevalence of NAFLD was 63 percent (63/100). In this investigation, gender, age > 48, BMI > 25 kg/m2, and diabetes mellitus duration > 10 years were all risk variables linked with the existence of NAFLD (p=0.0002). Conclusion:Present study highlighted the significant burden of Non-Alcoholic Fatty Liver Disease in cohort of type -2 Diabetes Mellitus. About half of the subjects had NAFLD (63%). In present study high BMI, and duration of diabetes > 10 years were positively correlated with NAFLD.

New therapy for fatty liver

2018 ◽  
Vol 1 (2) ◽  
pp. 24-28
Author(s):  
Tanita Suttichaimongkol
Keyword(s):  
Oxidative Stress ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lifestyle Modifications ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Liver Insulin Resistance ◽  
Alcoholic Fatty Liver Disease ◽  
Related Mortality

Non-alcoholic fatty liver disease (NAFLD) is a leading cause of death from liver cirrhosis, endstage liver disease, and hepatocellular carcinoma. It is also associated with increased cardiovasculardisease and cancer related mortality. While lifestyle modifications are the mainstay of treatment,only a proportion of patients are able to make due to difficult to achieve and maintain, and so moretreatment options are required such as pharmacotherapy. This review presents the drugs used inmanaging NAFLD and their pharmacologic targets. Therapies are currently directed towards improvingthe metabolic status of the liver, insulin resistance, cell oxidative stress, apoptosis, inflammation orfibrosis. Several agents are now in large clinical trials and within the next few years, the availability oftherapeutic options for NAFLD will be approved.     Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, fibrosis, cirrhosis  

Dapagliflozin reduces hepatic and visceral fat in type‐2 diabetes patients with non‐alcoholic fatty liver disease

2021 ◽  
Author(s):  
Susrichit Phrueksotsai ◽  
Kanokwan Pinyopornpanish ◽  
Juntima Euathrongchit ◽  
Apinya Leerapun ◽  
Arintaya Phrommintikul ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Visceral Fat ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease ◽  
Diabetes Patients
Sign in / Sign up

Export Citation Format

Share Document